Echocardiography

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Retrieved on: 
Monday, October 2, 2023
Columbia University, Columbia University Irving Medical Center, Male, ASNC, LV, LVH, N-terminal prohormone of brain natriuretic peptide, Cardiac amyloidosis, Serum, Secondary systemic amyloidosis, Echocardiography, IQR, Hypertrophic cardiomyopathy, ID, Assistant, SUV, ICC, ECV, CMP, ATTR, SAN, Map, Cardiology, Amyloidosis, Oregon Health and Science University Center for Women's Health, PET/CT, Genetic testing, Diagnosis, Liver, CMR, HCM, Society, Arnold, Disease, Medical imaging, Medical device, Hospital, Medicine, Patient, Heart

Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.

Key Points: 
  • Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.
  • AT-01 uptake in cardiac amyloidosis shows moderate and statistically significant correlations with traditional measures of cardiac structure and function.
  • These data were included in oral and poster presentations at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) taking place September 29-October 1, 2023, in Toronto, Canada.
  • These findings support the potential use of this novel imaging agent to monitor disease progression in patients with cardiac amyloidosis.

Icahn School of Medicine at Mount Sinai Awarded $10.2 Million NIH Grant to Explore the Early Signs of Arrhythmic Mitral Valve Prolapse

Retrieved on: 
Tuesday, September 26, 2023
Pi, American Heart Association, National Heart, Lung, and Blood Institute, Pathology, Arrhythmia, Doctor of Philosophy, Associate, Bangladesh Technical Education Board, Interventional radiology, Magnetic resonance imaging, Mitral regurgitation, Patient, Risk, Heart, Disease, Inflammation, Sudden death, Heart failure, Principal investigator, Diagnosis, Research, Prolapse, Cardiac electrophysiology, Mitral valve, Biomedical engineering, Death, Cardiac arrest, Mitral valve prolapse, Echocardiography, Stroke, Mount Sinai, Assistant, Fibrosis, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, Blood, PET, Shahid Gangalal National Heart Centre, Lung, MRI, Scientific Computing and Imaging Institute, Recurrence, Pharmaceutical industry, Medical device, Medical imaging, Radiology, MD, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse. This work aims to develop a better understanding of the condition and novel solutions to improve patient outcomes.

Key Points: 
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • In the United States, it is estimated that between 7 and 9 million people have mitral valve prolapse, the most common form of valve disease.
  • Mitral valve prolapse occurs when two flaps within the mitral valve don't close smoothly or evenly, but instead bulge (prolapse) upward into the left atrium when the heart contracts.

ModMed Introduces Maternal Fetal Medicine Addition to its OBGYN EHR Solution

Retrieved on: 
Tuesday, September 19, 2023
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Communication, Echocardiography, Senior counsel, Intelligent Medical Objects, OBGYN, Record, Multimedia, IMO, MD, EHR, Physician, Patient, Nursing, MFM

Medical practice leader, ModMed® , announced today the addition of maternal fetal medicine (MFM) capabilities into its electronic health record (EHR) suite for OBGYNs.

Key Points: 
  • Medical practice leader, ModMed® , announced today the addition of maternal fetal medicine (MFM) capabilities into its electronic health record (EHR) suite for OBGYNs.
  • View the full release here: https://www.businesswire.com/news/home/20230919581279/en/
    ModMed Introduces Maternal Fetal Medicine Addition to its OBGYN EHR Solution (Graphic: Business Wire)
    "ModMed's MFM incorporation into the OBGYN-EHR suite represents a significant advancement in providing comprehensive care and seamless communication between healthcare professionals," said Dr. Nigel Spier, Medical Director of OBGYN at ModMed.
  • Heather Stanley-Christian, MD, at Unity Maternal Fetal Medicine commented, “I've been thoroughly impressed by ModMed's OBGYN Practice Management software.
  • For more information about the ModMed OBGYN suite, please visit ModMed at modmed.com/resources/obgyn .

Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Clinician and San Diego Top Doctor to Scientific Advisory Board

Retrieved on: 
Monday, September 18, 2023
Health, Stem Cells, Other Health, General Health, Research, Science, Tri-City Medical Center, Anesthesiology, Aneurysm, COVID-19, DSM-IV codes, TSOI, Regenerative medicine, Chronic obstructive pulmonary disease, Chronic traumatic encephalopathy, Patient, B cell, FDA, Indian name, COVID19, Medical device, Pain management, Oncology, Echocardiography

Therapeutic Solutions International, Inc. (TSOI), announced today the appointment of internationally renowned stem cell therapist Dr. Navneet Boddu to the Company’s Scientific Advisory Board.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), announced today the appointment of internationally renowned stem cell therapist Dr. Navneet Boddu to the Company’s Scientific Advisory Board.
  • Dr. Boddu previously obtained for Therapeutic Solutions International Emergency IND approval to treat a patient with COVID-19 using JadiCells.
  • Therapeutic Solutions International plans to expand ongoing patient access to JadiCells as it advances in their development.
  • “Dr.

Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software

Retrieved on: 
Wednesday, September 13, 2023
Technology, Clinical Trials, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, PW, Heart, Duke University, CE, Partnership, Society, CW, American Society of Echocardiography, Health policy, Graduate Medical School Admissions Test, Heart failure, Anesthesiology, Echocardiography, Deep learning, Nasiriyah Heart Center, Splenic infarction, Associate, 2D, Duke University School of Medicine, Ischemia, Patient, Valvular heart disease, Algorithm, Artificial intelligence, Diagnosis, Cardiomyopathy, Duke University Health System, FDA, Pulmonary hypertension, Duke–NUS Medical School, Syndrome, Medtech, Medical device, Medical imaging, Doppler effect, Medicine

In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.

Key Points: 
  • In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.
  • Even at the most well-resourced setting, the process of acquiring, measuring, and analyzing the images is time-consuming and labor-intensive, making the routine echocardiography application unsustainable.
  • Advances in deep learning have made automated analysis of medical images possible,” said Dr. Manesh Patel, Chief of Cardiology and Co-Director of the Heart Center at Duke University Health System.
  • This covers the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Monday, September 11, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Heart, European Respiratory Society, International, PA, PAH, Echocardiography, The New England Journal of Medicine, MRK, Head, American Journal of Respiratory and Critical Care Medicine, Merck & Co., ERS, Resistance, Patient, N-terminal prohormone of brain natriuretic peptide, Mercury (element), Disease, Mortality, WHO, European Respiratory Journal, Orthostatic hypertension, International Congress on Tuberculosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Safety, Pharmaceutical industry, RV, Merck

Merck submitted an application for regulatory approval of sotatercept to the U.S. Food and Drug Administration and plans to submit applications to additional regulatory agencies worldwide.

Key Points: 
  • Merck submitted an application for regulatory approval of sotatercept to the U.S. Food and Drug Administration and plans to submit applications to additional regulatory agencies worldwide.
  • An exploratory post-hoc analysis from the STELLAR trial evaluated the effects of sotatercept on select hemodynamic parameters and right-ventricle (RV) function.
  • The STELLAR trial enrolled 323 adults with PAH, randomized to receive sotatercept (n=163) or placebo (n=160), on top of background therapy.
  • In the analysis, after 24 weeks, sotatercept was associated with meaningful improvements in certain measures of hemodynamic status and RV function.

CEUS Underutilization May Pose Greater Risk Than Rare Side Effects Associated With Use, Say Experts

Retrieved on: 
Friday, September 8, 2023
Other Health, General Health, Radiology, Philanthropy, Oncology, Medical Devices, Hospitals, Foundation, Cardiology, Biotechnology, FDA, Other Philanthropy, Health, CT, Radiation, UEA, University, GE HealthCare, Beth Israel Deaconess Medical Center, University of Nebraska Medical Center, Neoplasm, CEUS, Agent handling, Nebraska Medicine, Brain, Kidney, Assistant, Harvard Medical School, Allergy, Patient, Risk, Internal medicine, ICUS, MUGA, Research, Echocardiography, Death, Conference, SPECT, Medical imaging, Medical device, Vaccine, Medicine

He noted that UEAs present a rare risk of a severe allergic reaction in 1/15,000 patients.

Key Points: 
  • He noted that UEAs present a rare risk of a severe allergic reaction in 1/15,000 patients.
  • By comparison, iodinated contrast agents used for CT present a risk of life threatening reactions in 1/500 to 1/5,000 patients.
  • “Despite the rare risk of an adverse event associated with UEAs, patients face an even greater risk associated with non-use,” said Dr. Tom Porter, lead author of the ICUS guidelines.
  • He also said that CEUS use has even been associated with a reduced length of hospital stay in some patients.

Worldwide Medical Imaging Software Market 2023 Report: Market Predicted to Grow at a CAGR of 7.5% by 2031 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023
Medical Devices, Health, GE HealthCare, Prevalence, Investment, Echocardiography, 3D, Diagnosis, Research, 3D reconstruction, Government, MRI, Siemens Healthineers, Magnetic resonance imaging, Philips, Radiography, Growth, Conditional sentence, Bruker, Risk management, Medical device, Medical imaging, 3D printing, Pet industry, Marketing

The Medical Imaging Software market is poised for substantial growth, driven by various factors:

Key Points: 
  • The Medical Imaging Software market is poised for substantial growth, driven by various factors:
    Technological Advancement in Imaging Systems: Rapid advancements in imaging systems have paved the way for sophisticated medical imaging software.
  • These investments are expected to fuel the growth of the Medical Imaging Software market.
  • Medical imaging software plays a vital role in forming precise pictorial representations of scans, thereby facilitating medical investigations and diagnostic proceedings.
  • The market is witnessing constant enhancements in devices, driving the demand for medical imaging software and catalyzing overall market growth.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Friday, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Friday, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.